Skip to main content

Table 6 Major studies focus on the cfDNA plasma detection of ALK fusions

From: The value of cell-free circulating tumour DNA profiling in advanced non-small cell lung cancer (NSCLC) management

Reference Method of detection Study type/ Sample size Sensitivity/ PPA Specificity/ NPA Concordance/ OPA between tissue and liquid biopsy
Kunimasa et al. [87] PCR-based target sequencing ALK intron19 N = 20 50% 100% n.r
Mezquita et al. [88] Amplicon-based
(InVision™)
Retrospective
N = 59/6
ALK 78%/ROS1 100% n.r 86%
Schwartzberg et al. [61] NGS HiSeq® 2500 (Illumina) Prospective
N = 115
50% 100% 96%
Cui S et al. [89] Capture-based NGS N = 39 54% 100% n.r
Wang Ye et al. [90] Capture-based NGS N = 24 79% 100% 92%
Horn L et al. [92] Hybrid-capture system NGS
(Resolution Bioscience)
(Phase I/II multicohort eXalt2 trial)
N = 76 (22 with paired pre-treatment tissue and plasma)
n.r n.r 91%
Dagogo-Jack I et al. [91] Hybrid-capture next-generation sequencing Prospective
N = 22 with ALK progressive disease
86% ALK fusions
50% ALK mutations
n.r 100%
100%
  1. PPA Positive percent agreement, NPA Negative percent agreement, OPA overall percent agreement. n.r. not reported